FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136612769> ?p ?o ?g. }

• W2136612769 endingPage "54" @default.
• W2136612769 startingPage "43" @default.
• W2136612769 abstract "Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for treatment for coronary artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled trial we aimed to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent. Here we report secondary clinical and procedural outcomes after 1 year of follow-up.In a single-blind, multicentre, randomised trial, we enrolled eligible patients aged 18-85 years with evidence of myocardial ischaemia and one or two de-novo native lesions in different epicardial vessels. We randomly assigned patients in a 2:1 ratio to receive treatment with an everolimus-eluting bioresorbable scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) or treatment with an everolimus-eluting metallic stent (Xience, Abbott Vascular, Santa Clara, CA, USA). Randomisation was stratified by diabetes status and number of planned target lesions. The co-primary endpoints of this study are vasomotion (change in mean lumen diameter before and after nitrate administration at 3 years) and difference between minimum lumen diameter (after nitrate administration) after the index procedure and at 3 years. Secondary endpoints were procedural performance assessed by quantitative angiography and intravascular ultrasound; composite clinical endpoints based on death, myocardial infarction, and coronary revascularisation; device and procedural success; and angina status assessed by the Seattle Angina Questionnaire and exercise testing at 6 and 12 months. Cumulative angina rate based on adverse event reporting was analysed post hoc. This trial is registered at ClinicalTrials.gov, number NCT01425281.Between Nov 28, 2011, and June 4, 2013, we enrolled 501 patients and randomly assigned them to the bioresorbable scaffold group (335 patients, 364 lesions) or the metallic stent group (166 patients, 182 lesions). Dilatation pressure and balloon diameter at the highest pressure during implantation or postdilatation were higher and larger in the metallic stent group, whereas the acute recoil post implantation was similar (0.19 mm for both, p=0.85). Acute lumen gain was lower for the bioresorbable scaffold by quantitative coronary angiography (1.15 mm vs 1.46 mm, p<0.0001) and quantitative intravascular ultrasound (2.85 mm(2)vs 3.60 mm(2), p<0.0001), resulting in a smaller lumen diameter or area post procedure. At 1 year, however, cumulative rates of first new or worsening angina from adverse event reporting were lower (72 patients [22%] in the bioresorbable scaffold group vs 50 [30%] in the metallic stent group, p=0.04), whereas performance during maximum exercise and angina status by SAQ were similar. The 1-year composite device orientated endpoint was similar between the bioresorbable scaffold and metallic stent groups (16 patients [5%] vs five patients [3%], p=0.35). Three patients in the bioresorbable scaffold group had definite or probable scaffold thromboses (one definite acute, one definite sub-acute, and one probable late), compared with no patients in the metallic stent group. There were 17 (5%) major cardiac adverse events in the bioresorbable scaffold group compared with five (3%) events in the metallic stent group, with the most common adverse events being myocardial infarction (15 cases [4%] vs two cases [1%], respectively) and clinically indicated target-lesion revascularisation (four cases [1%] vs three cases [2%], respectively).The everolimus-eluting bioresorbable scaffold showed similar 1-year composite secondary clinical outcomes to the everolimus-eluting metallic stent.Abbott Vascular." @default.
• W2136612769 created "2016-06-24" @default.
• W2136612769 creator A5003299152 @default.
• W2136612769 creator A5015650103 @default.
• W2136612769 creator A5026031312 @default.
• W2136612769 creator A5029434010 @default.
• W2136612769 creator A5035239568 @default.
• W2136612769 creator A5036197968 @default.
• W2136612769 creator A5036968408 @default.
• W2136612769 creator A5038495074 @default.
• W2136612769 creator A5039055954 @default.
• W2136612769 creator A5041156414 @default.
• W2136612769 creator A5043059347 @default.
• W2136612769 creator A5051131587 @default.
• W2136612769 creator A5063792624 @default.
• W2136612769 creator A5069456501 @default.
• W2136612769 creator A5077459740 @default.
• W2136612769 creator A5081547954 @default.
• W2136612769 creator A5082907322 @default.
• W2136612769 date "2015-01-01" @default.
• W2136612769 modified "2023-10-16" @default.
• W2136612769 title "A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial" @default.
• W2136612769 cites W146325010 @default.
• W2136612769 cites W153981504 @default.
• W2136612769 cites W163964307 @default.
• W2136612769 cites W180536385 @default.
• W2136612769 cites W1840021307 @default.
• W2136612769 cites W1936833235 @default.
• W2136612769 cites W1958806846 @default.
• W2136612769 cites W1975007074 @default.
• W2136612769 cites W1981471804 @default.
• W2136612769 cites W1986708823 @default.
• W2136612769 cites W1993214130 @default.
• W2136612769 cites W1998542677 @default.
• W2136612769 cites W2008065895 @default.
• W2136612769 cites W2010080412 @default.
• W2136612769 cites W2016795245 @default.
• W2136612769 cites W2032897543 @default.
• W2136612769 cites W2040715270 @default.
• W2136612769 cites W2055215555 @default.
• W2136612769 cites W2059110168 @default.
• W2136612769 cites W2072974030 @default.
• W2136612769 cites W2086456362 @default.
• W2136612769 cites W2105813544 @default.
• W2136612769 cites W2107392339 @default.
• W2136612769 cites W2109647832 @default.
• W2136612769 cites W2123793954 @default.
• W2136612769 cites W2125407517 @default.
• W2136612769 cites W2136376838 @default.
• W2136612769 cites W2146743728 @default.
• W2136612769 cites W2157573306 @default.
• W2136612769 cites W2160414137 @default.
• W2136612769 cites W2160631086 @default.
• W2136612769 cites W2548646455 @default.
• W2136612769 cites W2762639187 @default.
• W2136612769 cites W2912662387 @default.
• W2136612769 cites W4293577771 @default.
• W2136612769 doi "https://doi.org/10.1016/s0140-6736(14)61455-0" @default.
• W2136612769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25230593" @default.
• W2136612769 hasPublicationYear "2015" @default.
• W2136612769 type Work @default.
• W2136612769 sameAs 2136612769 @default.
• W2136612769 citedByCount "492" @default.
• W2136612769 countsByYear W21366127692014 @default.
• W2136612769 countsByYear W21366127692015 @default.
• W2136612769 countsByYear W21366127692016 @default.
• W2136612769 countsByYear W21366127692017 @default.
• W2136612769 countsByYear W21366127692018 @default.
• W2136612769 countsByYear W21366127692019 @default.
• W2136612769 countsByYear W21366127692020 @default.
• W2136612769 countsByYear W21366127692021 @default.
• W2136612769 countsByYear W21366127692022 @default.
• W2136612769 countsByYear W21366127692023 @default.
• W2136612769 crossrefType "journal-article" @default.
• W2136612769 hasAuthorship W2136612769A5003299152 @default.
• W2136612769 hasAuthorship W2136612769A5015650103 @default.
• W2136612769 hasAuthorship W2136612769A5026031312 @default.
• W2136612769 hasAuthorship W2136612769A5029434010 @default.
• W2136612769 hasAuthorship W2136612769A5035239568 @default.
• W2136612769 hasAuthorship W2136612769A5036197968 @default.
• W2136612769 hasAuthorship W2136612769A5036968408 @default.
• W2136612769 hasAuthorship W2136612769A5038495074 @default.
• W2136612769 hasAuthorship W2136612769A5039055954 @default.
• W2136612769 hasAuthorship W2136612769A5041156414 @default.
• W2136612769 hasAuthorship W2136612769A5043059347 @default.
• W2136612769 hasAuthorship W2136612769A5051131587 @default.
• W2136612769 hasAuthorship W2136612769A5063792624 @default.
• W2136612769 hasAuthorship W2136612769A5069456501 @default.
• W2136612769 hasAuthorship W2136612769A5077459740 @default.
• W2136612769 hasAuthorship W2136612769A5081547954 @default.
• W2136612769 hasAuthorship W2136612769A5082907322 @default.
• W2136612769 hasConcept C126322002 @default.
• W2136612769 hasConcept C141071460 @default.
• W2136612769 hasConcept C164705383 @default.
• W2136612769 hasConcept C203092338 @default.
• W2136612769 hasConcept C2776931568 @default.
• W2136612769 hasConcept C2777546689 @default.
• W2136612769 hasConcept C2777785093 @default.

• next